ARS Pharmaceuticals, Inc. — Director's Dealing 2020

Dec 8, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Silverback Therapeutics, Inc. (SBTX)
CIK: 0001671858
Period of Report: 2020-12-08

Reporting Person: Alexandria Venture Investments, LLC (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-08	Common stock	C	699412	—	Acquired	699412	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-08	Series A redeemable convertible preferred stock	$	C	1428570	Disposed		Common stock (384748.0)	Direct
2020-12-08	Series B redeemable convertible preferred stock	$	C	1168347	Disposed		Common stock (314664.0)	Direct

Footnotes

F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.713 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on December 3, 2020, for no additional consideration. The shares had no expiration date.

F2: Not applicable.